Publications by authors named "Zhanybek Bokebaev"
Article Synopsis
- Scientists are working on developing drug delivery systems that target diseased tissues while minimizing side effects on healthy organs, with red blood cells (RBCs) showing potential as natural carriers due to their unique properties.
- Autologous RBCs (derived from a patient’s own blood) are especially promising for drug delivery due to their safety, immunogenic compatibility, and biodegradability.
- This review highlights advancements in encapsulating drugs into RBCs using osmotic methods, including clinical trial discussions and the need for automation in the production process to enhance the efficiency of targeted therapies.
Introduction: Using autologous erythrocytes as drug carriers for targeted delivery of cytokines to the sites of inflammation could potentially provide new opportunities for treatment of patients with purulent diseases. The targeted characteristic of erythrocytes is associated with the nature of purulent inflammation, where a large amount of erythrocytes is phagocytized and drugs encapsulated into the erythrocytes could be easily released. On the other hand, autologous erythrocytes meet all the criteria for the ideal drug carrier.
View Article and Find Full Text PDF